- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.06. | ACESO LIFE SCI (00474): NOTIFICATION OF BOARD MEETING | 2 | HKEx | ||
| 08.06. | ACESO LIFE SCI (00474): DISCLOSEABLE TRANSACTION DISPOSAL OF SHARES IN FUTURE DATA | - | HKEx | ||
| 26.05. | ACESO LIFE SCI (00474): DELAY IN DESPATCH OF CIRCULAR | 3 | HKEx | ||
| 04.05. | ACESO LIFE SCI (00474): CONNECTED AND MAJOR TRANSACTION SUBSCRIPTION OF SHARES INVOLVING ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE | 3 | HKEx | ||
| 03.03. | ACESO LIFE SCI (00474): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 03.03. | ACESO LIFE SCI (00474): DISCLOSABLE TRANSACTION COMPLETION OF SUBSCRIPTION OF SHARES INVOLVING ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE | 3 | HKEx | ||
| 27.02. | ACESO LIFE SCI (00474): SUPPLEMENTAL ANNOUNCEMENT DISCLOSEABLE TRANSACTION SUBSCRIPTION OF SHARES INVOLVING ISSUE OF CONSIDERATION SHARES UNDER GENERAL ... | 2 | HKEx | ||
| ACESO LIFE SCIENCE GROUP Aktie jetzt für 0€ handeln | |||||
| 30.01. | ACESO LIFE SCI (00474): DISCLOSABLE TRANSACTION SUBSCRIPTION OF SHARES INVOLVING ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 13.01. | ACESO LIFE SCI (00474): HIGH CONCENTRATION OF SHAREHOLDING | - | HKEx | ||
| 13.01. | ACESO LIFE SCI (00474): SFC ANNOUNCEMENT - HIGH CONCENTRATION OF SHAREHOLDING | 3 | HKEx | ||
| 30.12.25 | ACESO LIFE SCI (00474): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| 30.12.25 | ACESO LIFE SCI (00474): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| 30.12.25 | ACESO LIFE SCI (00474): INTERIM REPORT 2025 | 1 | HKEx |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GENERATE BIOMEDICINES | 15,430 | 0,00 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 5,025 | -0,10 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Reaffirms guidance to resubmit Anaphylm (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union... ► Artikel lesen | |
| KARDIGAN | 22,230 | -0,04 % | Kardigan, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 64,66 | -0,72 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 33,480 | -0,03 % | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine) | IMPAVIDO is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening... ► Artikel lesen | |
| NOVO NORDISK | 41,290 | -0,72 % | Novo Nordisk: Daten-Alarm - Hacker drohen mit Leak | Novo Nordisk steht nach einem schweren Cyberangriff unter Druck. Die Hackergruppe FulcrumSec droht mit der Veröffentlichung sensibler Unternehmensdaten, nachdem der dänische Ozempic-Hersteller ein Lösegeld... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 14,690 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| TRULIEVE CANNABIS | 7,740 | -0,51 % | Trulieve's NYSE Listing Is Historic. But Is the Stock Still Worth Buying? | ||
| SEAPORT THERAPEUTICS | 18,950 | -0,11 % | Seaport Therapeutics Prices Upsized IPO Of 14.16 Mln Shares At $18 Each | WASHINGTON (dpa-AFX) - Seaport Therapeutics, Inc. (SPTX) said it has priced its upsized initial public offering of 14.16 shares at $18 per share, at the top of the target range. The company... ► Artikel lesen | |
| ATRIUM THERAPEUTICS | 12,830 | +0,16 % | Atrium Therapeutics Reports First Quarter 2026 Financial Results | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company... ► Artikel lesen | |
| JOURNEY MEDICAL | 6,690 | -0,15 % | Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million Emrosi revenues were $6.3 million in the first quarter ended March 31, 2026 Cash position increased... ► Artikel lesen | |
| CDT EQUITY | 1,140 | -0,87 % | CDT Equity's Sarborg stake valued at $127.5M after fundraise | ||
| INHIBIKASE THERAPEUTICS | 1,865 | -0,27 % | Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity | WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 49,120 | +0,61 % | Milliarden für Forschung, Milliarden für Übernahmen: Warum die größten Biotech-Gewinner oft außerhalb Deutschlands entstehen | ||
| INCYTE | 92,00 | +0,24 % | Analgesundheit raus aus der Tabuzone: Incyte ebnet mit der Kampagne "Die letzten 3cm zählen" den Weg für mehr Offenheit und Aufklärung | München (ots) - Gesundheitsthemen brauchen Offenheit - gerade dort, wo im Alltag noch immer viel Scham oder Unsicherheit mitschwingt. Aus Angst vor Peinlichkeit und Stigmatisierung verschweigen viele... ► Artikel lesen |
Das Unternehmen ACESO LIFE SCIENCE GROUP LTD kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACESO LIFE SCIENCE GROUP LTD finden Sie auf Wallstreet Online.